REGNNEUTRAL

Revenue Growth (YoY)

19.0%

Higher than 85% of Healthcare sector peers

Updated 268h ago

Sector Performance

85th percentile

REGN

19.0%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

Revenue Growth (Year-over-Year) measures the percentage change in a company's sales compared to the same quarter one year earlier.

REGN's current revenue growth of 19.0% is well above the healthcare sector median of 6.2%, placing it in the 85th percentile among industry peers. The trend direction over the last eight quarters is not available (N/A), as are the year-over-year and quarter-over-quarter changes, so no recent trajectory can be assessed. The combination of a high current growth level with no trend data suggests the stock may still offer a near-term opportunity from strong recent performance, but the lack of sequential or historical context introduces uncertainty about sustainability. This strong relative growth supports the overall NEUTRAL verdict by indicating the company is outperforming its sector on this metric, but without clear momentum or deterioration, it does not justify a bullish or bearish shift.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about REGN?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does REGN's Revenue Growth (YoY) compare to its sector?

REGN's Revenue Growth (YoY) of 19.0% compares to a Healthcare sector median of 6.2%, placing it in the 85th percentile.

Who are REGN's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ABT (7.8%), ZBH (9.3%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.